B of A Securities Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Geoff Meacham maintains a Buy rating on Lyell Immunopharma (NASDAQ:LYEL) but lowers the price target from $9 to $6.
June 27, 2024 | 5:28 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
B of A Securities maintains a Buy rating on Lyell Immunopharma but lowers the price target from $9 to $6, indicating a cautious optimism.
The Buy rating suggests continued confidence in the company's long-term prospects, but the lowered price target reflects a more conservative short-term outlook. This mixed signal may result in neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100